Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Interest & Investment Income: 2015-2025

Historic Interest & Investment Income for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $5.4 million.

  • Spyre Therapeutics' Interest & Investment Income rose 3.76% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 19.63%. This contributed to the annual value of $21.3 million for FY2024, which is 246.71% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Interest & Investment Income of $5.4 million as of Q3 2025, which was down 8.43% from $5.9 million recorded in Q2 2025.
  • Spyre Therapeutics' Interest & Investment Income's 5-year high stood at $6.5 million during Q1 2025, with a 5-year trough of $19,000 in Q2 2021.
  • Its 3-year average for Interest & Investment Income is $4.1 million, with a median of $5.2 million in 2024.
  • In the last 5 years, Spyre Therapeutics' Interest & Investment Income tumbled by 93.67% in 2021 and then spiked by 1,591.43% in 2024.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Interest & Investment Income stood at $34,000 in 2021, then skyrocketed by 1,105.88% to $410,000 in 2022, then surged by 906.34% to $4.1 million in 2023, then soared by 39.99% to $5.8 million in 2024, then climbed by 3.76% to $5.4 million in 2025.
  • Its Interest & Investment Income stands at $5.4 million for Q3 2025, versus $5.9 million for Q2 2025 and $6.5 million for Q1 2025.